Stock screener

CADL

Conviction 80HealthcareScan · Thu, Sep 24, 2026

Candel Therapeutics, Inc. (CADL) closed at $11.56 (+2.39%) on Sep 24, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 49, RS Rating 96, -15.9% from its 52-week high, +112.5% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).

CADL$11.56+2.39%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 1.37M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Candel Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.candeltx.com ↗
Price11.56
Change+2.39%
Gap-1.11%
Rel volume0.97×
Avg volume1.24M
Avg $ vol14.51M
SMA 2011.96
SMA 5011.35
SMA 2007.82
Price vs 50+1.83%
Price vs 200+47.75%
MA stackbullish
50/200 cross—
Supertrenddown · 13.04
RSI (14)49
MACD hist-0.09
MACD cross—
Stoch %K / %D53 / 50
ADX (14)26
+DI / −DI17 / 21
RSI divergence—
MACD divergence—
ATR %6.58%
ADR %6.14%
52w high13.75
52w low4.42
From 52w high-15.93%
Above 52w low+161.54%
New 52w highNo
SqueezeOff
Bollinger width32.23%
%B0.40
Donchian pos41.13%
Donchian high14.00
Donchian low9.86
AVWAP (52w high)11.70
vs AVWAP high-1.15%
AVWAP (52w low)7.93
vs AVWAP low+45.80%
OBV trendDown
Chaikin MF (20)-0.14
Today vs 20d0.97×
Avg vol (14d)1.37M
Avg vol (20d)1.24M
Avg $ vol (20d)14.51M
Market cap884.55M
RS Rating96 / 99
RS 3m (vs SPY)+17.58%
RS 6m (vs SPY)+114.85%
RS line new highNo
Trend template8/8
Technical rank81.0
1 week+1.94%
1 month-15.00%
3 months+22.07%
6 months+131.66%
1 year+118.53%
YTD+112.50%
P/E-23.17
P/B7.01
P/S—
P/FCF-22.74
EPS-0.7200
Div yield—
ROE-30.27%
ROA-18.34%
Debt/Eq0.01
Current16.09
EV/EBITDA-14.42
Gross margin—
Net margin—
Rev growth0.00%
EPS growth30.80%
Price target21.67
Target upside87.46%
Analyst ratingBuy
Institutional69.05%
Ent. value684.72M
Revenue31K
Net income-38.91M
Gross profit—
Free cash flow-38.9M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out73.27M
Employees55
ListedTue, Jul 27, 2021
Free float42.26M
Float %77.0%
Short interest12.27M
Days to cover9.2d
Short volume57.3%
Squeeze score77 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.35 vs −$0.22
Last surprise-59.1% miss
Setup gradeA
Conviction80 / 100
Pattern quality—
Tech rank81.0 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance13.91
Support10.10
Days since event—
Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CADL

All disclosures →
No recent disclosed trades by Congress in CADL. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CADL · open-market 3 sells

InsiderSideShares
Tak Paul Peter
Chief Executive Officer · Common Stock · 2026-09-11
Sell59.38K
Tak Paul Peter
Chief Executive Officer · Common Stock · 2026-09-10
Sell220.87K
Tak Paul Peter
Chief Executive Officer · Stock Option (Right to Buy) · 2026-09-10
Exercise125K
Tak Paul Peter
Chief Executive Officer · Common Stock · 2026-09-10
Exercise125K
Tyagarajan Seshu
Chief Technology Officer · Common Stock · 2026-08-17
Sell7K
Sims Mark E.
Chief Commercial Officer · Stock Option (Right to Buy) · 2026-07-06
Grant285K
Manning Paul B
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K
Gaeta Renee
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K
Nguyen Diem
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K
Radhakrishnan Maha
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K

SEC filings

EDGAR filings in CADL · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.